Put companies on watchlist
Hardman & Co Research
ISIN: GB00B5SGVL29
WKN: A1C0FE
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Hardman & Co Research · ISIN: GB00B5SGVL29 · EQS - Company News (4 News)
Country: Great Britain · Primary market: United Kingdom · EQS NID: 1876877
10 April 2024 08:15AM

Six consecutive periods of >20% growth


Hardman & Co Research
Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth

10-Apr-2024 / 07:15 GMT/BST
The issuer is solely responsible for the content of this announcement.


Hardman & Co Research on Tissue Regenix (TRX):

Six consecutive periods of >20% growth

 

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023. New growth in 2024 will deliver a fully profitable, cash-generative, group. The cash will be invested to expand capacity even further through Phase 2, starting in 2025.

 

Please click on the link below for the full report:

https://hardmanandco.com/research/corporate-research/trx_six-consecutive-periods-of-20-growth/

If you are interested in meeting the company, you can register your interest by clicking on the above link.

To contact us:

Hardman & Co

9 Bonhill Street

London

EC2A 4DJ
www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall


 

 

mh@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1876877  10-Apr-2024 

fncls.ssp?fn=show_t_gif&application_id=1876877&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Hardman & Co Research
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.